Detection, distribution, and pathologic significance of BK virus strains isolated from patients with kidney transplants, with and without polyomavirus-associated nephropathy.
Context.--BK virus strains or regulatory region sequence variations
may play a role in the pathogenesis of polyomavirus-associated
nephropathy (PVAN), although no definite relationship has yet been
Objective.--To investigate the pathologic significance of BK virus strains and regulatory region sequence variations.
Design.--Eight (3.5%) of 226 patients with renal transplants developed PVAN; the remaining 218 cases were used as controls. From the patients who developed PVAN, 70 urine samples, 63 blood samples, and 17 renal biopsy samples were taken, and 682 urine samples, 677 blood samples, and 101 renal biopsy samples were taken from the control cases. Amplification and sequence analyses of regulatory region were obtained, and the sequences were analyzed using the Basic Local Alignment Search Tool program.
Results.--The WWT strain was more frequently detected in PVAN cases than in the control cases (urine: 88.5% vs 22.1%; blood: 85.2% vs 40%; renal biopsies: 77.8% vs 0%), and the AS and WW strains were only isolated from controls. Strain 128-1 was frequently associated with JC virus coinfection in both groups (PVAN: 78.3%; controls: 98%). Major WWT rearrangements were detected in 29.6% of the urine samples, 30.4% of the blood samples, and one renal biopsy from the PVAN cases, but in only one urine sample from the controls. Insertion of 8 base pairs (P block) was found in all 128-1 strains; WW and AS were archetypal in 78.9% and 57.7% of the samples, respectively.
Conclusions.--Although the study included only 8 PVAN cases, regulatory region sequence variations seem to be frequent and independent of the development of the disease, and the WWT strain seems more frequently related to the development of nephropathy than other strains.
Polyoma virus (Risk factors)
Kidney diseases (Development and progression)
Kidney diseases (Care and treatment)
Kidney diseases (Patient outcomes)
Kidneys (Complications and side effects)
|Publication:||Name: Archives of Pathology & Laboratory Medicine Publisher: College of American Pathologists Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 College of American Pathologists ISSN: 1543-2165|
|Issue:||Date: May, 2009 Source Volume: 133 Source Issue: 5|
Polyomavirus-associated nephropathy (PVAN) is a tubular
interstitial inflammatory disease caused by lytic infection of
epithelial tubular cells by human BK polyomavirus (BKV) in patients who
have undergone kidney transplantation. First described by Mackenzie in
1978, (1) it has been recognized with increasing frequency (especially
because of the introduction of new triple-drug immunosuppression
regimens, including a calcineurin inhibitor, mycophenolate mofetil, and
prednisone) and is currently considered to be one of the leading causes
of graft loss. (2) The natural history of BKV infection starts with a
generally asymptomatic primary infection during childhood; after which,
the virus becomes latent in the renourinary epithelium, where its
replication is controlled by immunosurveillance mechanisms. Impaired
immune function caused by physiologic (older age, pregnancy) or
pathologic conditions (acquired immunodeficiency syndrome,
immunosuppression therapy) can reactivate the virus and cause the lysis
of cells targeted by viral infection, (3) the cytologic expression of
which is the presence of "decoy cells" in urinary specimens.
(4) BK virus reactivation can give rise to hemorrhagic cystitis,
ureteritis, or PVAN (5);the first 2 may occur under various conditions
of immune suppression, but PVAN is much more common in patients who have
undergone renal transplantation, although it is also reported
sporadically in recipients of solid organ transplant and patients with
acquired immunodeficiency syndrome. (6)
Hirsch and Steiger (7) have suggested that PVAN is the result of interactions between the host (ie, typically men older than 50 years), graft (ischemic injury during surgery), and viral factors, including viral genotypes, related to nucleotide sequences of the polymorphic sites in the viral protein (VP) 1 region (genotypes I-VI), and viral strains, which can be distinguished by the structure of their transcriptional control region (TCR). (8) The TCR has been arbitrarily divided into 5 transcription factor binding blocks (O, P, Q, R, and S) and contains factor binding sites that control the expression of early genes (small t and large T antigens) and late genes that encode capsid proteins (VP1, VP2, and VP3) and the agnoprotein. (9)
The WW BKV strain, which consists of O (142 base pairs [bp]), P (63 bp), Q (39 bp), R (63 bp), and S (63 bp) of the TCR region, has been called archetypal by Sugimoto et al, (10) and any deviation from this structure is considered a rearranged form, (11) including single nucleotide polymorphisms and the deletion, insertion, or duplication of blocks of sequences (major rearrangements). Rearranged viral strains may occur in vitro (after repeated passages in cell cultures) (12) or in human hosts and have been found in various specimens and tissues as well as in different clinical settings. (13,8)
It has been hypothesized that specific TCR sequence variations may be related to increased replication activity and infectiousness, as reported for the other member of the human polyomavirus (PV) family, and that JC virus (JCV), in what is called a progressive multifocal leukoencephalopathy-like rearrangement, is required for the development of progressive multifocal leukoencephalopathy (PML). (14) A few studies (15-20) have considered the possibility that specific BKV TCR sequence variations are related to the development of PVAN, but the results have, so far, been discordant, and their real significance in human hosts has not yet been defined.
The sequence analysis of the TCR of BKV isolated from urine, blood, and renal biopsy samples has not yet been established as a means of diagnosing PVAN, which, therefore, still relies on a histologic and/or immunohistochemical demonstration of BKV infection in the epithelial tubular cells or in the parietal cells of the Bowman capsule in renal biopsies. (21) However, a large number of decoy cells in urine, as well as the presence of BKV DNA in urine and blood, and a viral load more than 10000 copies/mL, are considered useful for monitoring and selecting patients at risk of developing PVAN during kidney transplant. (22)
We have previously analyzed TCR sequence variations in BKV that were detected in various samples taken from patients with PVAN in an attempt to verify whether specific BKV strains play a role in the development and/or severity of the disease. (19) The results indicated that such variations were independent of the presence and severity of the cell damage detected in urine and renal biopsy samples, but that study (19) only included patients who had already developed PVAN.
The aims of this study were (1) to verify whether there are any differences in the frequency of BKV strains or TCR sequence variations between patients with kidney transplant, with and without PVAN; and (2) to investigate whether the sequence analysis of the TCR of BKV can be used in the diagnosis or management of PVAN.
MATERIALS AND METHODS
The study involved 226 recipients of renal allograft who were admitted to the transplant unit of Novara hospital in Italy between 2001 and 2007. During the study, 8 patients developed PVAN (3.5%), 5 men and 3 women, with an average age of 51 years (range, 36-65 years); the other 218 (96.5%) patients, 118 men and 100 women, with an average age of 51.6 years (range, 22-76 years) were used as a control group. Table 1 shows the main clinical and pathologic characteristics of the patients with PVAN. Polyomavirus-associated nephropathy was diagnosed by detection of viral inclusions in the tubular epithelial cells or Bowman capsule parietal cells in allograft biopsies that were immunohistochemically stained for polyomavirus proteins. There was no significant difference in basic immunosuppressive therapy between the 2 groups, and one or more rejection episodes were experienced in both groups.
Paired urine and blood samples were collected after renal transplantation to screen for, and monitor, PVAN using the current guidelines drawn up by an international multidisciplinary panel23; renal biopsies were performed in the cases of suspected PVAN, when renal function worsened, and in cases of persistent disease. There was, therefore, a considerable difference in the number of samples taken from each group, depending on the development of PVAN: the patients in the PVAN group provided 70 urine samples (range, 5-14; mean, 8.7 samples each), 63 blood samples (range, 5-14; mean, 8 samples each), and 17 renal biopsy samples (range, 1-5; mean, 2.1 samples each), as shown in Table 2; and patients in the control group provided 682 urine samples (range, 1-11; mean, 3.1 samples each), 677 blood samples (range, 1-11; mean 3.1 samples each), and 101 renal biopsy samples, taken from 68 patients (range, 1-5; mean 1.5 samples each).
Urine Samples.--The urine samples were concentrated by means of centrifugation at 700g for 10 minutes, and 5 mL of the urine pellets were then cytocentrifuged at 250g for 10 minutes onto 2 slides, both of which were fixed in 95% ethanol, stained with Papanicolaou stain, and cytologically examined to identify the presence of decoy cells, indicating active PV replication. (4)
Blood Samples.--The blood samples (5 mL) were collected and immediately centrifuged at 700g for 10 minutes; after which, the serum was separated and stored in a 1.5-mL tube at --20[degrees]C.
Renal Biopsies.--Three fragments of renal tissue for each sample were obtained (using a 18-gauge needle), fixed in Serra fluid (ethanol, formaldehyde, and acetic acid) for 4 hours, and embedded in paraffin; 4-[micro]m-thick sections were then stained with hematoxylin-eosin, periodic acid-Schiff, silver methenamine, Masson trichrome, and phosphotungstic acid hematoxylin. After antigen retrieval with ethylenediaminetetraacetic acid at pH 8 and microwaving at 900 W (2 steps of 3 minutes, followed by 2 steps of 4 minutes), immunoperoxidase staining was performed using a polyclonal antibody against the VP1 through VP3 proteins of simian virus 40 (dilution, 1:20000; Lee Biomolecular Research Labs, San Diego, Calif), which cross-reacts with human BKV and JCV. (24) The reactions were detected by means of the streptavidin-biotin method and were revealed using diaminobenzidine as the chromogen.
A histologic diagnosis of PVAN was made only when epithelial nuclei showing the morphologic changes reported by Nickeleit et al (25) were identified by light microscopy and positively stained by immunohistochemistry.
DNA Extraction.--Four 4-[micro]m-thick sections were cut from the paraffin-embedded renal tissue samples and placed into 1.5-mL Eppendorf tubes, with the microtome blade being cleaned with xylene between each block to avoid sample cross-contamination. (26) DNA was extracted with ethylenediaminetetraacetic acid-sodium dodecyl sulfate-proteinase K, followed by phenol-chloroform, as previously reported, (27) and resuspended with 30 [micro],L of diethyl pyrocarbonate-treated and autoclaved pyrogen and RNase-free water. All of the samples underwent spectrometric analysis using a Biophotometer (Eppendorf, Hamburg, Germany) and were diluted to a concentration of 50 ng/[micro],L before being tested in a multiplex nested polymerase chain reaction (PCR).
DNA was extracted from the serum samples using commercial columns (Nucleospin virus, Macherey-Nagel, Germany) with a silica matrix and high DNA-binding capacity.
Nested PCR of the [beta]-actin gene was performed in all cases as a positive control of DNA extraction.
PCR Assay.--To amplify the large T regions, a multiplex nested PCR was performed directly on the urine samples (as proposed by Agostini et al (28)) and on the DNA extracted from all of
the renal and serum samples using PM1+ and PM1--as outer primers, and PM2-- (common to all PVs), JC+ (an amplified fragment of 189 bp), BK+ (an amplified fragment of 353 bp), and simian virus 40+ (an amplified fragment of 135 bp) as inner primers, all simultaneously mixed in a single reaction to distinguish the different members of the Polyomavirus genus (29) (Table 3). The samples were amplified in a total volume of 25 [micro]L, containing 2 U of BioTaq DNA polymerase (Bioline, London, England) in the presence of 1X ammonium buffer (Bioline), 2 mM magnesium chloride (1 mM for the inner PCR), 5 pmol/[micro]Lof each primer (Roche Diagnostics, Milan, Italy), 0.2 mM deoxyribonucleotide triphosphates (Roche Diagnostics, Milan, Italy), and 10 [micro]L of serum DNA, 5 [micro]L of renal tissue DNA, 2.5 [micro]L of urine, and 1 [micro]L of template in the inner PCR reactions using a Eppendorf Mastercycler gradient PCR system. The procedure involved denaturation at 95[degrees]C for 5 minutes, followed by 40 cycles (35 cycles for the inner PCR) of denaturation at 95[degrees]C for 40 seconds, annealing at 61 [degrees]C (55[degrees]C for the inner PCR) for 40 seconds, and extension at 72[degrees]C for 40 seconds. The cycles were terminated with a final extension at 72[degrees]C for 5 minutes. Diethyl pyrocarbonatetreated, RNase-free water (Biotecx Labs, Houston, Tex) was used as the negative control; the positive controls were DNA extracted from brain tissue from a patient with PML (for JCV), renal tissue from a patient with histologically proven BKV nephropathy (for BKV), and from an simian virus glia cell line culture (for simian virus 40). The sensitivity of the multiplex nested PCR was estimated by amplifying serial dilutions of a JCV+ sample (data not shown).
The samples positive for the large T antigen region of BKV underwent further amplification of the TCR region using BKTT1 and BKTT2 as outer primers and BRP1 and BRP2 (an amplified 356-bp fragment of the archetype) as inner primers (Table 3). The amplification was performed in a total volume of 25 [micro]L, containing 10 pmol/[micro]L of each primer, 0.2 mM deoxyribonucleotide triphosphates, 1.5mM magnesium chloride, and 2 U BioTaq DNA polymerase in the presence of 1X ammonium buffer (Bioline) and 2mM magnesium chloride. In the first step, 5 [micro]L of renal tissue DNA, serum DNA, or urine were added to the PCR mixture, and in the second step, 2.5 [micro]L of template was added; the PCR was then performed using a Mastercycler gradient (Eppendorf) PCR system. The samples were amplified by means of denaturation at 95[degrees]C for 5 minutes, followed by 35 cycles at 95[degrees]C for 40 seconds, annealing at 55[degrees]C for 40 seconds (50[degrees]C for the inner PCR), and extension at 72[degrees]C for 40 seconds; the cycles were terminated with a final extension at 72[degrees]C for 5 minutes.
All of the DNA amplification products were analyzed by means of 2% agarose gel electrophoresis and visualized using ethidium bromide staining; because of the frequent TCR se quence variations, the size of the PCR amplification fragments could differ from the expected 356 bp of the archetype.
[FIGURES 1-2 OMITTED]
Direct DNA Sequencing.--DNA fragments from all the TCRpositive samples were separated by electrophoresis on 3% agarose gel, and 1 to 3 fragments of each sample (300-400 bp) were excised, extracted, and purified using a commercial kit (PCR clean-up gel extraction, NucleoSpin Macherey-Nagel, Dliren, Germany).
A cycle-sequencing PCR reaction was set up using the Big Dye Version 2.0 Terminator cycle-sequencing kit (Applied Biosystems, Monza, Italy), with the primer being added to a final concentration of 3.2 pmol/^L in a total volume of 20 [micro]L. The cycling conditions were 25 cycles at 96[degrees]C for 10 seconds, 50[degrees]C for 5 seconds, and 60[degrees]C for 4 minutes; the reaction was terminated at 4[degrees]C. The cycle sequencing products were purified using Centri-Sep Spin Columns (Princeton Separations, Adelphia, NJ), and the DNA was sequenced using an automated 16 capillary sequencer (ABI-Prism 3100, Applied Biosystems, Monza, Italy).
The sequences were analyzed by means of the Basic Local Alignment Search Tool programs using a Web site maintained by the US National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). The structure of the BKV TCR isolates was compared with that of the archetypal BKV WW and
BKV WWT strains, according to Sundsfjord et al, (12) and the BKV 128-1 strain (GenBank Accession AF218446).
The data were statistically analyzed using Fisher exact test, with P values <.05 considered significant (95% confidence interval).
Eight (3.5%) of the 226 patients with renal transplants developed PVAN, which was diagnosed on the basis of renal biopsy histology, through the detection of typical intranuclear viral inclusions as reported by Nickeleit et al, (25) and immunohistochemical analysis (Figure 1, A and B).
Multiplex nested PCR detected PV genome in 68 (97.1%) of 70 urine samples, 36 (57.1%) of 63 blood samples, and 13 (76.5%) of 17 renal biopsy samples. In the control group, among the 218 (96.5%) of the 226 patients with renal transplants who did not develop PVAN, PV was identified in 242 (35.5%) of 682 urine samples, 24 (3.5%) of 677 blood samples, and 5 (5%) of 101 renal biopsy samples.
JC virus was never detected alone in any of the PVAN samples but was the prevalent PV in the urine samples of
the control patients (19.4% JCV vs 8.6% BKV, 7.5% BKV JCV coinfection; P < .001); BKV was detected alone or in association with JCV only in the PVAN group (Figure 2).
Only 2 BKV strains were detected in patients with PVAN: WWT and 128-1 (Figure 3, A and B); WWT was the predominant strain in the urine, blood (P < .001), and renal biopsy samples (P = .06) when BKV was detected alone, but interestingly, all of the BKV isolated from urine and blood and 4 (80%) of the 5 strains isolated from renal biopsies showed 128-1 TCR architecture when associated with JCV coinfection. The prevalence of 128-1 in mixed infection was significantly higher than that of BKV infection alone in the urine and blood samples (P < .001) and was also higher in the renal biopsy samples, although this difference was not statistically significant (P = .06).
The control patients showed a wider range of BKV strains: in addition to WWT and 128-1, AS and WW strains were also identified. When BKV was detected alone, the WW strain was the most frequently isolated strain in urine (P < .001), but when BKV was found coinfecting with JCV, 128-1 prevailed in the urine, blood, and renal biopsy samples (P < .001).
Comparison of the BKV strains detected in the 2 groups of patients by type of sample showed that WWT was significantly more frequent in the urine and blood samples taken from the PVAN group than from the control group (P < .001), and this difference was even more striking in the case of the renal biopsy samples (WWT was never detected in any of the control samples). AS and WW strains were only detected in patients without PVAN and were detected with different frequencies in the urine, blood, and renal biopsy samples. Finally, in the cases of BKV-JCV coinfection, the BKV 128-1 strain was isolated more prevalently from all examined samples from both groups of patients.
Tables 4 through 7 show detailed analyses of the TCR region of the different BKV strains. The TCR sequences analyzed in patients with PVAN had an archetypal architecture in only one blood sample (BKV WWT). A single base pair substitution (g[right arrow]a, at position S18) was the most frequent TCR variation in the WWT strain in the urine (59.3%), blood (65.2%), and renal biopsy samples (100%). P block duplications and deletions were detected in 29.6% of the WWT strains isolated from the urine samples, 30.4% of those isolated from the blood samples, and in one BKV detected with JCV in one renal biopsy sample.
Major rearrangements were found in all the BKV 128-1 strains. A constant finding was the insertion of an 8 bp in position 41 of the P block, sometimes in association with more complex variations in TCR anatomy (ie, the duplication of a block of sequences) or single base pair substitutions.
In the control group, the WWT strain showed the same single base pair substitution as that detected in patients with PVAN (g[right arrow], at position S18) in almost all cases; WWT archetypal architecture was found in only 2 urine samples with BKV-JCV coinfection. Similar to the findings from the PVAN group, no archetypal BKV 128-1 architecture was ever identified, but the same 8-bp insertion in position 41 of the P block was detected in association with major rearrangements or with single base pair substitutions.
The WW and AS strains were only identified in the controls. The TCR architecture of both was archetypal in all renal biopsies samples and in most of the urine samples in which major rearrangements consisted of deletions
(WW and AS) and duplications of the P block (WW), and
single base pair substitutions (WW) were also identified (29.7%). In the blood samples, the WW strain was always archetypal, whereas AS variously showed an archetypal structure (40%), single base pair substitutions (20%), and deletion of the P block (40%).
Sequential samples taken from each patient (before, during, and after the diagnosis of PVAN) showed that the TCR structure was highly stable; there were no changes in strains or sequence variations during the study period.
The BKV regulatory region, which is located between the DNA replication origin and the agnoprotein gene, has many important functions: transcriptional regulation of the early and late coding regions, control of viral replication by means of promoter-enhancer sequences, and the regulation of host cell oncogenes (c-myc) and tumor suppressor genes (p53 and pRb). (9)
DNA sequencing of different BKV isolates has shown that the coding regions of BKV (large and small T, agnoprotein, and viral capsid protein genes) have strong sequence conservation (reviewed by Jin et al30), but the TCR is subject to considerable variations. As these results were first obtained in laboratory models after cell culture passages, the hypervariability of the TCR was initially interpreted as being caused by viral adaptation to the cell culture milieu,31 but the direct sequencing of BKV strains isolated from healthy humans or from patients with different diseases has shown that such sequence variations may also occur naturally. (8) However, their underlying mechanisms and pathologic significance are still unclear: we (19) have examined the frequency of BKV TCR sequence variations in patients with renal transplants who developed PVAN, as have others, (15-18,20) to investigate possible correlations between the variations and the pathogenesis of renal damage, but, to our knowledge, no clear link has ever been demonstrated.
One crucial point in the management of PVAN is that its diagnosis requires the recognition of BKV inclusions in renal tubule epithelial cells or Bowman capsule parietal cells in allograft biopsy specimens. (21) Noninvasive methods, such as the cytologic analysis of urine to search for decoy cells or qualitative and quantitative PCR on urine and blood, are useful in selecting patients with renal transplants who are at risk of developing PVAN and in monitoring treatment efficacy, (22) but not in formulating a definite diagnosis. Nevertheless, at least theoretically, identifying nephritogenic BKV strains or specific TCR sequence variations in urine or blood of patients with renal transplants and PVAN, by means of PCR and sequence analysis, could have practical importance in diagnosing the disease without the need for a renal biopsy, in the same way that identifying PML-like strains in the cerebrospinal fluid of patients with PML can allow a definite diagnosis in appropriate clinical settings.
On the basis of these considerations, we used PCR amplification and direct sequencing of the BKV TCRs isolated from urine, blood, and renal biopsy samples (1) to verify whether there were any significant differences in the BKV strains isolated from patients with renal transplants, either with and without PVAN; (2) to identify the TCR sequence variations that were only detectable in patients with PVAN; and (3) to establish whether the sequence analysis of BKV TCRs may be of practical use in the diagnosis or management of PVAN.
With regard to the first point, our findings showed that the BKV WWT strain was significantly more frequent in the urine and blood samples taken from patients with PVAN and, more interesting, that WWT was isolated in the renal biopsy samples of the patients with PVAN but never detected in the samples taken from the control group. Furthermore, the WW and AS strains were never isolated in the patients with PVAN but were frequently found in the control group.
Given the large number of blood and urine samples examined, these findings seem to indicate that the BKV strains were nonrandomly distributed in the 2 populations, although a definite link between a specific BKV strain and renal damage cannot be proven with certainty. BK virus WWT was first isolated in urine samples from Norway by Sundsfjord et al (12) and was considered a natural variant of the archetype BKV WW that permitted more efficient viral replication activity in host cells. Olsen et al (20) have recently reported that WWT was the most frequent BKV strain isolated in 11 patients with renal transplants (including 7 with PVAN), but the small number of samples examined and the small number of cases without PVAN make that study not entirely comparable with ours.
Sequence analysis of the TCRs of the BKV strains found in both groups in our study revealed a variety of sequence variations, most of which were single base pair substitutions, but there were also major rearrangements, including the deletion or duplication of blocks of sequences. Sequence variations were identified in all 128-1 strains and in all but 2 WWT strains (isolated in urine samples taken from the control group), whereas the AS and WW strains, which were only detected in the control group, had an archetypal architecture in all the renal biopsy samples and most of the blood and urine samples.
Analysis of these data seems to exclude the possibility that specific base pair substitutions or major rearrangements are required for the development of PVAN, but their significance remains controversial. A review by Moens et al13 has made it clear that BKV sequence variations can be detected in samples of various tissues taken from healthy subjects, patients with renal transplants both with and without PVAN, patients with immunosuppressed and immunocompetent systems, and patients with neoplastic conditions or autoimmune diseases; so, the sequence analysis of TCRs cannot predict cell tropism or diseases with strain-specific associations. Similar conclusions were drawn by Sharma et al (8) who made a meta-analysis of 507 TCR sequences: although TCR sequence variations were more frequent in the samples taken from patients with PVAN than from those with asymptomatic viruria, no definite cause-effect relationship in the pathogenesis of virusmediated renal damage was found. One possible explanation (suggested by Moens et al (13)) is that renal disease is associated with a high degree of viral replication activity and a large number of viral copies, thus leading to a greater likelihood of viral recombination. However, when we compared BKV TCR sequence variations with the presence and strength of viruria (evaluated as the number of decoy cells) in a recent study, (19) we did not find any relationship because similar sequence variations were detected with both the presence and absence of decoy cells.
Another interesting finding of the present study is that the WWT strains isolated from the renal biopsies of patients with PVAN always showed only single base pair substitutions when detected alone (ie, without JCV coinfection), which is in line with the finding by Randhawa et al17 that single nucleotide substitutions were the most frequent sequence variations in 26 renal biopsies taken from 15 patients with PVAN.
Finally, most of the patients with BKV-JCV coinfection in both groups had rearranged BKV 128-1 strains. The significance of this finding is unknown, but it can be hypothesized that 128-1 (which has never previously been reported in patients with renal transplants) needs JCV coinfection to persist in patients with renal transplants or that there may be reciprocal interactions between the 2 PVs, similar to that reported for other viruses. (32)
In conclusion, our data indicate that BKV TCR sequence variations are frequent in patients with renal transplants regardless of the development of PVAN; moreover, although the small number of patients with PVAN in the study does not allow any definite conclusions, the prevalence of the WWT strain in the renal tissue of patients with PVAN could suggest an association between it and the development of renal disease. Sequence analysis of the TCRs of BKV isolated from patients with renal transplants may be useful in predicting the possible development of renal damage but does not seem to be essential for a definite diagnosis of PVAN.
We thank Silvano Andorno, MD, for statistical support. This study was supported in part by grant 2006 Ricerca Sanitaria Finalizzata from the Regione Piemonte, Torino, Italy (Boldorini).
(1.) Mackenzie EF, Poulding JM, Harrison PR, Amer B. Human polyoma virus (HPV)--a significant pathogen in renal transplantation. Proc Eur Dial Transplant Assoc. 1978;15:352-360.
(2.) Bresollette-Bodin C, Coste-Burel M, Hourmant M, Sebile V, Andre Garnier E, Imbert-Marcile BM. A prospective Longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant. 2005;5:1926-1933.
(3.) Kwak EJ, Vilchez RA, Randhawa P, Shapiro R, Butel JS, Kusne S. Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis. 2002;35:1081-1087.
(4.) Koss L. Diagnostic Cytology and its Histopathologic Bases. 3rd ed. Philadelphia, Pa: JB Lippincott; 1979:711-748.
(5.) Boubenider S, Hiesse C, Marchand S, Hafi A, Kriaa F, Charpentier B. Posttransplantation polyomavirus infections.J Nephrol. 1999;12:24-29.
(6.) Sukov WR, Lewin M, Sethi S, Rakowski TA, Lager DJ. BK virus-associated nephropathy in a patient with AIDS. Am J Kidney Dis. 2008;51:15-18.
(7.) Hirsh HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003;3:61 1-623.
(8.) Sharma PM, Gupta G, Vats A, Shapiro R, Randhawa PS. Polyomavirus BK non-coding control region rearrangements in health and disease. J Med Virol. 2007;79:1199-1207.
(9.) Moens U, Rekvig OP. Molecular biology of BK virus and clinical and basic aspects of BK virus renal infection. In: Khalili K, Stoner GL, eds. Human Polyomaviruses: Molecular and Clinical Perspectives. New York, NY: Wiley-Liss Inc; 2001:359-408.
(10.) Sugimoto C, Hara K, Taguchi F, Yogo Y. Regulatory DNA sequence conserved in the course of BK virus evolution. J Mol Evol. 1990;3:485-492.
(11.) Chatterjee M, Weyandt TB, Frisque RJ. Identification of archetype and rearranged forms of BK virus in leukocytes from healthy individuals. J Med Virol. 2000;60:353-362.
(12.) Sundsfjord A, Johansen T, Flaegstad T, et al. At least two types of control regions can be found among naturally occurring BK virus strains. J Virol. 1990; 64:3864-3871.
(13.) Moens U, Van Ghelue M. Polymorphism in the genome of non-passaged human polyomavirus BK: implications for cell tropism and the pathological role of the virus. Virology. 2005;331:209-231.
(14.) Yogo Y, Sugimoto C. The archetype concept and regulatory region rearrangement. In: Khalili K, Stoner GL, eds. Human Polyomaviruses: Molecularand Clinical Perspectives. NewYork, NY: Wiley-Liss Inc; 2001:127-149.
(15.) Baksh FK, Finkelstein SD, Swalsky PA, Stoner GL, Ryschkewitsch CF, Randhawa P. Molecular genotyping of BK and JC viruses in human polyomavirusassociated interstitial nephritis after renal transplantation. Am JKidneyDis. 2001; 38:354-365.
(16.) Chen CH, Wen MC, Wang M, et al. A regulatory region rearranged BK Virus is associated with tubularinterstitial nephritis in a rejected renal allograft. J MedVirol. 2001;64:82-88.
(17.) Randhawa P, Zygmunt D, Shapiro R, et al. Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney Int. 2003;64:743-747.
(18.) Azzi A, De Santis R, Salotti V, Di Pietro N, Ginevri F, Comoli P. BK virus regulatory region sequence deletions in a caseofhuman polyomavirusassociated nephropathy (PVAN) after kidney transplantation. JClinVirol. 2006;35:106-108.
(19.) Boldorini R, Veggiani C, Turello E, Barco D, Monga G. Are sequence variations in the BK virus control region essential for the development of polyomavirus nephropathy? Am J Clin Pathol. 2005;124:303-312.
(20.) Olsen GH, Andresen PA, Hilmarsen HT, et al. Genetic variability in BK Virus regulatory regions in urine and kidney biopsies from renal-transplant patients. JMedVirol. 2006;78:384-393.
(21.) NickeleitV, Singh HK, Mihatsch MJ. Polyomavirus nephropathy: morphology, pathophysiology, and clinical management. Curr Opin Nephrol Hypertens. 2003;12:599-605.
(22.) Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis. 2006;8:76-85.
(23.) Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79:1277-1286.
(24.) Shinohara T, Matsuda M, Cheng SH, Marshall J, Fujita M, Nagashima K. BK virus infection of the human urinary tract. JMedVirol. 1993;41:301-305.
(25. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant. 2000;15:324-332.
(26.) Wright DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: Innis MA, Gelfand DH, Svinskyy JJ, White TJ, eds. PCR Protocols. San Diego, Calif: Academic Press; 1990:153-158.
(27.) Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, Vago L, Boldorini R, Costanzi G. PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. JMedVirol. 1995;47:219 225.
(28.) Agostini HT, Brubaker GR, Shao J, et al. BK virus and a new type of JC virus excreted by HIV-1 positive patients in rural Tanzania. ArchVirol. 1995;140: 1919-1934.
(29.) Fedele CG, Ciardi M, Delia S, Echevarria JM, Tenorio A. Multiplex polymerase chain reaction for the simultaneous detection and typing ofpolyomavirus JC, BK and SV40 DNA in clinical samples. JVirol Meth. 1999;82:137-144.
(30.) Jin L, Gibson PE, Booth JC, Clewley JP. Genomic typing of BK virus in clinical specimens by direct sequencing of polymerase chain reaction products. J Med Virol. 1993;41:11-17.
(31.) Ferguson AT, Subramani S. Complex functional interactions at the early enhancer of the PQ strain of BK virus. JVirol. 1994;68:4274-4286.
(32.) Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issue. Nat Rev Cancer. 2007;7:11-22. Accepted for publication August 11, 2008.
From the Department of Medical Science, University School of Medicine "Amedeo Avogadro" of Eastern Piedmont (Dr Boldorini, Ms Allegrini, Mr Miglio, and Ms Paganotti); and the Unit of Pathology, Ospedale Maggiore della Carita (Dr Boldorini and Ms Veggiani), Novara, Italy.
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Renzo Boldorini, MD, Department of Dragon Psychology, Dipartimento di Scienze Mediche, Facolta di Medicina e Chirurgia, Universita del Piemonte Orientale "Amedeo Avogadro," Via Solaroli 17, 28100 Novara, Italy (e-mail: firstname.lastname@example.org).
Table 1. Main Clinicopathologic Findings in Recipients of Renal Transplants Who Developed Polyomavirus-Associated Nephropathy (PVAN) Age of Case Transplant, Renal Disease Leading to No. Age, y/Sex mo. Chronic Renal Failure * 1 61/M 60 Polycystic kidney disease 2 36/F 48 IgA PVAN 3 57/M 60 Polycystic kidney disease 4 58/M 36 Unknown 5 53/F 48 Arterionephrosclerosis 6 41/M 24 Nephroangiosclerosis 7 65/M 12 Glomerular disease 8 38/F 12 IgA PVAN * IgA indicates immunoglobulin A. Table 2. Distribution of Samples in Relation to the Diagnosis of Polyomavirus-Associated Nephropathy (PVAN) Before PVAN, No. Initial Diagnosis of PVAN, No. Patient Renal Renal No. Urine Blood Biopsy Urine Blood Biopsy 1 1 0 1 1 1 1 2 1 0 0 1 1 1 3 1 1 0 1 1 1 4 1 1 0 1 1 1 5 2 2 0 1 1 1 6 2 2 2 1 1 1 7 1 1 0 1 1 1 8 2 2 0 1 1 1 Persistency of After PVAN, No. PVAN, No. Patient Renal Renal No. Urine Blood Biopsy Urine Blood Biopsy 1 0 0 0 6 6 3 2 6 5 0 3 1 0 3 6 6 2 6 6 0 4 4 4 1 2 2 0 5 6 5 0 3 3 0 6 2 2 0 2 1 0 7 1 1 0 2 2 0 8 2 2 0 0 0 0 Table 3. Genomic Sequence and Position of Polyomavirus Primers for the Large T, Transitional Control Region (TCR), and TCR Sequence Region Primer Position Name Large T Outer PM1+ 4022-4045 ([dagger]) PM1- 4550-4572 ([dagger]) Inner PM2- 4388-4411 ([dagger]) JC+ 4086-4108 ([double dagger]) SV+ 4291-4314 ([section]) BK+ 4059-4085 ([dagger]) TCR BK virus Outer BKTT1 5106-5133 ([dagger]) BKTT2 630-657 ([dagger]) Inner BRP1 82-101 ([dagger]) BRP2 339-358 ([dagger]) Region Sequence * Large T Outer 5'-TCT TCT GGR YTA AAR TCA TGC TCC-3' 5'-TTW TAG RTK CCA ACC TAT GGA AC-3' Inner 5'-GGT AGA AGA CCC YAA RGA CTT TCC-3' 5'-ATA TTA TGA CCC CCA AAA CCA TG-3' 5'-ATA ATT TTC TTG TAT AGC AGT GCA-3' 5'-GAA TGC TTT CTT CTA TAG TAT GGT ATG-3' TCR BK virus Outer 5'-AAG GTC CAT GAG CTC CAT GGA TTC TTC C-3' 5'-CTA GGT CCC CCA AAA GTG CTA GAG CAG C-3' Inner 5'-TTG AGA GAA AGG GTG GAG GC-3' 5'-GCC AAG ATT CCT AGG CTC GC-3' * Wobble position from the International Union of Biochemistry (IUB) code: Y = C/T; R = A/G; W = A/T; K = G/T. ([dagger]) BK virus Dunlop strain. ([double dagger]) JC virus complete genome. ([section]) Simian virus 40 complete genome. Table 4. BK Virus (BKV) Transcriptional Control Region (TCR) Rearrangements in Urine, Blood, and Renal Biopsy Samples From Patients With Polyomavirus-Associated Nephropathy: BKV Infection Alone Sample, No. (%) * Rearrangement ([dagger]) Urine BKV WWT (N = 54) 0 Archetype 32 (59.3) g [right arrow] a (S18) 11 (20.5) [DELTA](P32-P49); g [right arrow] a (S18) 1 (1.8) rep (P51-Q26); g [right arrow] a (S18) 6 (11.1) g [right arrow] a (S5); g [right arrow] a (S18) 2 (3.7) [DELTA](P41-P60); g [right arrow] a (S18) 1 (1.8) rep (P48-P50); g [right arrow] a (S18) 1 (1.8) rep (P48-P50); g [right arrow] t (Q29); g [right arrow] a (S18) BKV 128-1 (N = 7) 0 Archetype 1 (14.3) ins 8 bp (P41) 5 (71.4) ins 8 bp (P41); g [right arrow] t (S22) 1 (14.3) rep (P15-P40); ins 8 bp (P41); g [right arrow] t (S22) Blood BKV WWT (N = 23) 1 (4.3) Archetype 15 (65.3) g [right arrow] a (S18) 5 (21.8) [DELTA](P32-P49); g [right arrow] a (S18) 1 (4.3) rep (P66-Q20) 1 (4.3) [DELTA](P60-Q26); g [right arrow] a (S18) BKV 128-1 (N = 4) 0 Archetype 4 (100) ins 8 bp (P41); g [right arrow] t (S22) Renal biopsy BKV WWT (N = 7) 0 Archetype 7 (100) g [right arrow] a (S18) BKV 128-1 (N = 2) 0 Archetype 1 (50) ins 8 bp (P41); g [right arrow] t (S22) 1 (50) ins 8 bp (P41); g [right arrow] t (S22); rep (P56-S35) * The percentage of archetypes and TCR rearrangements has been calculated for each strain in the different samples. ([dagger]) [right arrow] indicates substitution; bp, base-pair; ins, insertion; rep, repetition; A, deletion. Table 5. BK Virus (BKV) Transcriptional Control Region (TCR) Rearrangements in Urine, Blood, and Renal Biopsy Samples From Patients With Polyomavirus-Associated Nephropathy: BKV-JC Virus Coinfection Sample, No. (%) * Rearrangement Urine BKV 128-1 (N = 24) 0 Archetype 3 (12.5) ins 8 bp (P41) 16 (66.6) ins 8 bp (P41); g [right arrow] t (S22) 2 (8.3) [DELTA](P39-P41) 1 (4.2) ins 8 bp (P41); g [right arrow] t (S22); c [right arrow] t (Q39); rep (P13-Q26) 1 (4.2) ins 8 bp (P41); rep (P24-R2); g [right arrow] t (S22) 1 (4.2) ins 8 bp (P41); rep (P17-Q35); [DELTA](R24-S63) Blood BKV 128-1 (N = 19) 0 Archetype 13 (68.3) ins 8 bp (P41); g [right arrow] t (S22) 1 (5.3) ins 8 bp (P41); g [right arrow] t (S22); a [right arrow] t (S27) 1 (5.3) ins 8 bp (P41); [DELTA](R1-R47); g [right arrow] t (S22) 1 (5.3) ins 8 bp (P41); [DELTA](Q38-R52); g [right arrow] t (S22) 1 (5.3) ins 8 bp (P41); rep (P25-R4); g [right arrow] t (S22) 2 (10.5) ins 8 bp (P41); a [right arrow] t (Q31); g [right arrow] t (S22); rep (P16-Q33) Renal biopsy BKV WWT (N = 1) 0 Archetype 1 (100) [DELTA](P32-P49); g [right arrow] a (S18) BKV 128-1 (N = 4) 0 Archetype 4 (100) ins 8 bp (P41); g [right arrow] t (S22) * The percentage of archetypes and TCR rearrangements has been calculated for each strain in the different samples. ([dagger]) [right arrow] indicates substitution; bp, base-pair; ins, insertion; rep, repetition; A, deletion. Table 6. BK Virus (BKV) Transcriptional Control Region (TCR) Rearrangements in Urine, Blood, and Renal Biopsy Samples From Patients With Kidney Transplants Without Polyomavirus-Associated Nephropathy: Control Group BKV Infection Alone Sample, No. (%) * Rearrangement ([dagger]) Urine BKV WWT (N = 13) 0 Archetype 13 (100) g [right arrow] a (S18) BKV WW (N = 29) 22 (75.9) Archetype 1 (3.4) rep (P31-Q7) 1 (3.4) [DELTA](P8-P26) 4 (13.9) c [right arrow] t (Q8) 1 (3.4) c [right arrow] t (P31) BKV AS (N = 17) 9 (53) Archetype 8 (47) [DELTA] (P42-P49) Blood BKV WWT (N = 4) 0 Archetype 4 (100) g [right arrow] a (S18) BKV WW (N = 1) 1 (100) Archetype BKV AS (N = 5) 2 (40) Archetype 2 (40) [DELTA] (P42-P49) 1 (20) g [right arrow] a (S25) Renal biopsy BKV 128-1 (N = 1) 0 Archetype 1 (100) ins 8 bp (P41); rep (P19-P52); g [right arrow] t (S22) BKV WW (N = 1) 1 (100) Archetype BKV AS (N = 1) 1 (100) Archetype * The percentage of archetypes and TCR rearrangements has been calculated for each strain in the different samples. ([dagger]) [right arrow] indicates substitution; bp, base-pair; ins, insertion; rep, repetition; [DELTA], deletion. Table 7. BK Virus (BKV) Transcriptional Control Region (TCR) Rearrangements in Urine, Blood, and Renal Biopsy Samples From Patients With Kidney Transplants Without Polyomavirus-Associated Nephropathy: Control Group BKV-JC Virus Coinfection Sample, No. (%) * Rearrangement Urine BKV WWT (N = 14) 2 (14.3) Archetype 11 (78.6) g [right arrow] a (S18) 1 (7.1) [DELTA](P41-P49) BKV 128-1 (N = 38) 0 Archetype 26 (68.4) ins 8 bp (P41); g [right arrow] t (S22) 1 (2.6) ins 8 bp (P41); g [right arrow] a (P42); g [right arrow] t (S22) 2 (5.4) g [right arrow] t (S22) 1 (2.6) c [right arrow] a (R12); g [right arrow] t (S22) 1 (2.6) a [right arrow] t (S2 7) 2 (5.4) [DELTA](P20-P26); ins 8 bp (P41); g [right arrow] t (S22) 1 (2.6) ins 8 bp (P41) 1 (2.6) [DELTA](P42-P55); ins ctca(P60); rep (P51- S35); g [right arrow] t (S22) 1 (2.6) [DELTA](P42-P55); ins ctca(P60); rep (P51- S35); g [right arrow] t (S22); [DELTA](R6-R10) 1 (2.6) ins 8 bp (P41); [DELTA](P42-P51); g [right arrow] t (S22); a [right arrow] t (S2 7) 1 (2.6) ins 8 bp (P41); [DELTA](P42-P51); g [right arrow] t (S22); [DELTA](R6-R10) BKV WW (N = 5) 4 (80) Archetype 1 (20) [DELTA](P8-P26) BKV AS (N = 3) 3 (100) Archetype 0 Rearrangement Blood BKV WW (N = 2) 2 (100) Archetype BKV 128-1 (N = 9) 0 Archetype 7 (77.8) ins 8 bp (P41); g [right arrow] t (S22) 1 (11.1) ins 8 bp (P41) 1 (11.1) ins 8 bp (P41); g [right arrow] t (S22); rep (P15-P40) Renal biopsy BKV 128-1 (N = 1) 0 Archetype 1 (100) ins 8 bp (P41); g [right arrow] t (S22) * The percentage of archetypes and TCR rearrangements has been calculated for each strain in the different samples. ([dagger]) [right arrow] indicates substitution; bp, base-pair; ins, insertion; rep, repetition; [DELTA], deletion. Figure 3. Distribution of BK polyomovirus (BKV) strains in urine, blood, and renal biopsy samples showing A, BKV infection alone or B, BKV and JC virus (JVC) coinfection. PVAN indicates polyomavirus associated nephopathy. Figure 3. A URINE 128-1 PVAN Group 7/61 11.5% Control Group 0/59 0% WWT PVAN Group 54/61 83.5% Control Group 13/59 22.1% WW PVAN Group 0/61 49.1% Control Group 29/59 0% AS PVAN Group 0/61 0% Control Group 17/59 28.8% BLOOD 128-1 PVAN Group 4/27 14.8% Control Group 0/27 0.% WWT PVAN Group 23/27 85.2% Control Group 4/10 40.0% WW PVAN Group 0/27 10.0% Control Group 1/10 0% AS PVAN Group 0/27 0% Control Group 5/10 50.0% RENAL BIOPSY 128-1 PVAN Group 2/9 22.2% Control Group 1/3 33.3% WWT PVAN Group 7/9 77.8% Control Group 0/3 0% WW PVAN Group 0/9 0% Control Group 1/3 33.4% AS PVAN Group 0/9 0% Control Group 1/3 33.3% Total strains Figure 3A URINE 128-1 PVAN Group 24/24 100.0% Control Group 38/60 63.3% WWT PVAN Group 0/24 0% Control Group 14/60 23.3 WW PVAN Group 0/24 0% Control Group 5/60 8.3% AS PVAN Group 0/24 0% Control Group 3/60 5.1% BLOOD 128-1 PVAN Group 19/19 100.0% Control Group 9/11 81.8% WWT PVAN Group 0/19 0% Control Group 0/11 0% WW PVAN Group 0/19 0% Control Group 2/11 18.2% AS PVAN Group 0/19 0% Control Group 0/11 0% RENAL BIOPSY 128-1 PVAN Group 4/5 80.0% Control Group 1/1 100.0% WWT PVAN Group 1/5 20.0% Control Group 0/1 0% WW PVAN Group 0/5 0% Control Group 0/1 0% AS PVAN Group 0/5 0% Control Group 0/1 0% Total strains
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|